ACADIA Pharmaceuticals Q1 2024 Earnings Report $15.38 -0.74 (-4.59%) As of 04:00 PM Eastern Earnings HistoryForecast ACADIA Pharmaceuticals EPS ResultsActual EPS$0.10Consensus EPS $0.04Beat/MissBeat by +$0.06One Year Ago EPS-$0.27ACADIA Pharmaceuticals Revenue ResultsActual Revenue$205.83 millionExpected Revenue$208.31 millionBeat/MissMissed by -$2.48 millionYoY Revenue Growth+73.80%ACADIA Pharmaceuticals Announcement DetailsQuarterQ1 2024Date5/8/2024TimeAfter Market ClosesConference Call ResourcesConference CallConference Call TranscriptSlide DeckPress ReleaseACAD Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Slide DeckFull Screen Slide DeckPowered by Remove Ads ACADIA Pharmaceuticals Earnings HeadlinesSoleno jumps as analysts say US nod for rare disease drug transforms treatment optionsMarch 27, 2025 | reuters.comIs ACADIA Pharmaceuticals Inc. (ACAD) a Promising Biotech Stock According to Wall Street AnalystsMarch 25, 2025 | msn.com"King of the Quants”: Please don’t take this warning lightly…Decades ago, before quantitative models were common on Wall Street, one investor built a system so effective it earned him the nickname "King of the Quants" from Forbes. Now, that same system has uncovered a rare market phenomenon — one he hasn’t seen in 30 years. The last time something like this happened, it created life-changing wealth for some and financial ruin for others. But this time, he says, the outcome could be even more dramatic. The shakeup ahead might be unlike anything we’ve seen before.April 4, 2025 | InvestorPlace (Ad)Stoke Therapeutics reports Q EPS (18c), consensus (53c)March 19, 2025 | markets.businessinsider.comIs ACADIA Pharmaceuticals Inc. (ACAD) the Best Nasdaq Stock Under $20 to Buy Now?March 18, 2025 | msn.comAcadia Pharmaceuticals issues new employee stock awardsMarch 16, 2025 | investing.comSee More ACADIA Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like ACADIA Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ACADIA Pharmaceuticals and other key companies, straight to your email. Email Address About ACADIA PharmaceuticalsACADIA Pharmaceuticals (NASDAQ:ACAD), a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.View ACADIA Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Lamb Weston Stock Rises, Earnings Provide Calm Amidst ChaosIntuitive Machines Gains After Earnings Beat, NASA Missions AheadCintas Delivers Earnings Beat, Signals More Growth AheadNike Stock Dips on Earnings: Analysts Weigh in on What’s NextAfter Massive Post Earnings Fall, Does Hope Remain for MongoDB?Semtech Rallies on Earnings Beat—Is There More Upside?These 3 Q1 Earnings Winners Will Go Higher Upcoming Earnings Bank of New York Mellon (4/11/2025)BlackRock (4/11/2025)JPMorgan Chase & Co. (4/11/2025)Progressive (4/11/2025)Wells Fargo & Company (4/11/2025)Interactive Brokers Group (4/15/2025)Bank of America (4/15/2025)Citigroup (4/15/2025)Johnson & Johnson (4/15/2025)Morgan Stanley (4/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
